SG10202102125SA - Use of known compounds as d-amino acid oxidase inhibitors - Google Patents
Use of known compounds as d-amino acid oxidase inhibitorsInfo
- Publication number
- SG10202102125SA SG10202102125SA SG10202102125SA SG10202102125SA SG10202102125SA SG 10202102125S A SG10202102125S A SG 10202102125SA SG 10202102125S A SG10202102125S A SG 10202102125SA SG 10202102125S A SG10202102125S A SG 10202102125SA SG 10202102125S A SG10202102125S A SG 10202102125SA
- Authority
- SG
- Singapore
- Prior art keywords
- amino acid
- known compounds
- acid oxidase
- oxidase inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03003—D-Amino-acid oxidase (1.4.3.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
- G16C20/64—Screening of libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
- G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
- G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
- G01N2333/90644—D-Amino acid oxidase (1.4.3.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Library & Information Science (AREA)
- Computing Systems (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461986480P | 2014-04-30 | 2014-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202102125SA true SG10202102125SA (en) | 2021-04-29 |
Family
ID=54359315
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607166XA SG11201607166XA (en) | 2014-04-30 | 2015-04-30 | Use of known compounds as d-amino acid oxidase inhibitors |
SG10202102125SA SG10202102125SA (en) | 2014-04-30 | 2015-04-30 | Use of known compounds as d-amino acid oxidase inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607166XA SG11201607166XA (en) | 2014-04-30 | 2015-04-30 | Use of known compounds as d-amino acid oxidase inhibitors |
Country Status (15)
Country | Link |
---|---|
US (2) | USRE49340E1 (en) |
EP (2) | EP3137658B1 (en) |
JP (2) | JP2017524143A (en) |
KR (2) | KR20160147868A (en) |
CN (2) | CN112773798B (en) |
AU (1) | AU2015253099B2 (en) |
CA (1) | CA2946153C (en) |
DK (1) | DK3137658T3 (en) |
ES (2) | ES2951736T3 (en) |
IL (1) | IL248567B (en) |
MX (2) | MX2016011551A (en) |
PT (1) | PT3137658T (en) |
SG (2) | SG11201607166XA (en) |
TW (1) | TWI675660B (en) |
WO (1) | WO2015168346A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2951736T3 (en) * | 2014-04-30 | 2023-10-24 | Univ Nat Taiwan | Use of compounds known as D-amino acid oxidase inhibitors |
EP4289425A2 (en) * | 2016-09-14 | 2023-12-13 | Yufeng Jane Tseng | Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors |
CN108143734A (en) * | 2018-02-09 | 2018-06-12 | 南京中医药大学 | The application of amodiaquine and its pharmaceutically acceptable salt in the drug for treating Alzheimer disease is prepared |
CN110297839B (en) * | 2019-06-25 | 2022-04-12 | 中国人民解放军军事科学院军事医学研究院 | Drug indication query method and device, computer equipment and storage medium |
CA3166147A1 (en) * | 2021-06-23 | 2022-12-23 | Yoda Pharmaceuticals Inc. | Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4619652A (en) | 1982-12-23 | 1986-10-28 | Alza Corporation | Dosage form for use in a body mounted pump |
JPH0347123A (en) | 1989-05-05 | 1991-02-28 | G D Searle & Co | Therapeutic composition for cns disease con- taining indole-2-carboxylate compounds |
GB9208492D0 (en) | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
GB9304500D0 (en) | 1993-03-05 | 1993-04-21 | Glaxo Spa | Heterocyclic compounds |
GB9321221D0 (en) | 1993-10-14 | 1993-12-01 | Glaxo Spa | Heterocyclic compounds |
JP3928000B2 (en) * | 1995-11-13 | 2007-06-13 | 昭子 板井 | Method for designing bioactive compounds |
JP2004515477A (en) * | 2000-12-07 | 2004-05-27 | ニューロモレキュラー インコーポレイテッド | Methods for treating neuropsychiatric disorders using NMDA receptor antagonists |
US20030162825A1 (en) | 2001-11-09 | 2003-08-28 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
WO2003097011A1 (en) * | 2002-05-17 | 2003-11-27 | Eisai Co., Ltd. | Compositions and methods using proton pump inhibitors |
CA2559105A1 (en) | 2004-03-16 | 2005-09-29 | Janssen Pharmaceutica N.V. | Benzisoxazoles |
EP1747800B1 (en) * | 2005-07-29 | 2009-03-18 | Rottapharm S.p.A. | Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders |
US20090306169A1 (en) * | 2005-10-06 | 2009-12-10 | Brandish Philip E | Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors |
EP1998766A2 (en) * | 2005-12-16 | 2008-12-10 | Ironwood Pharmaceuticals, Inc. | Useful indole compounds |
AU2007249348C1 (en) * | 2006-05-10 | 2013-01-17 | Laclede, Inc. | Compositions and methods for enzymatic treatment of lung disorders |
CA2659060A1 (en) * | 2006-06-30 | 2008-01-10 | Sepracor Inc. | Fused heterocyclic inhibitors of d-amino acid oxidase |
JP2010516697A (en) * | 2007-01-18 | 2010-05-20 | セプラコール インク. | D-amino acid oxidase inhibitor |
JP2011522043A (en) * | 2008-06-02 | 2011-07-28 | アイロンウッド ファーマシューティカルズ, インコーポレイテッド | Carboxylic acid derivatives of selenophene and selenazole |
JP4462382B1 (en) * | 2009-04-23 | 2010-05-12 | 学校法人北里研究所 | Novel inhibitors for D-aspartate oxidase and D-amino acid oxidase |
US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
JO3115B1 (en) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | Pyridazinone Compounds and Their Use as DAAO Inhibitors |
US20130116215A1 (en) * | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
KR101348984B1 (en) * | 2012-01-31 | 2014-01-10 | 전남대학교산학협력단 | Novel preparation method of metabolites of omeprazole using bacterial cytochrome P450 and composition therefor |
ES2951736T3 (en) * | 2014-04-30 | 2023-10-24 | Univ Nat Taiwan | Use of compounds known as D-amino acid oxidase inhibitors |
-
2015
- 2015-04-30 ES ES19150604T patent/ES2951736T3/en active Active
- 2015-04-30 US US16/401,892 patent/USRE49340E1/en active Active
- 2015-04-30 DK DK15786611.2T patent/DK3137658T3/en active
- 2015-04-30 KR KR1020167032409A patent/KR20160147868A/en not_active Application Discontinuation
- 2015-04-30 US US15/125,716 patent/US9868975B2/en not_active Ceased
- 2015-04-30 AU AU2015253099A patent/AU2015253099B2/en active Active
- 2015-04-30 EP EP15786611.2A patent/EP3137658B1/en active Active
- 2015-04-30 IL IL248567A patent/IL248567B/en unknown
- 2015-04-30 PT PT157866112T patent/PT3137658T/en unknown
- 2015-04-30 CN CN202011486413.7A patent/CN112773798B/en active Active
- 2015-04-30 TW TW104114104A patent/TWI675660B/en active
- 2015-04-30 KR KR1020227029414A patent/KR102537686B1/en active IP Right Grant
- 2015-04-30 WO PCT/US2015/028385 patent/WO2015168346A1/en active Application Filing
- 2015-04-30 CA CA2946153A patent/CA2946153C/en active Active
- 2015-04-30 SG SG11201607166XA patent/SG11201607166XA/en unknown
- 2015-04-30 JP JP2017510438A patent/JP2017524143A/en active Pending
- 2015-04-30 ES ES15786611T patent/ES2911879T3/en active Active
- 2015-04-30 EP EP19150604.7A patent/EP3498275B1/en active Active
- 2015-04-30 SG SG10202102125SA patent/SG10202102125SA/en unknown
- 2015-04-30 CN CN201580021632.9A patent/CN106687626B/en active Active
- 2015-04-30 MX MX2016011551A patent/MX2016011551A/en unknown
-
2016
- 2016-09-06 MX MX2021000133A patent/MX2021000133A/en unknown
-
2020
- 2020-03-03 JP JP2020035496A patent/JP6941326B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272130B (en) | Inhibitors of lysine specific demethylase-1 | |
IL251584B (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
IL248505A0 (en) | Inhibitors of lysine specific demethylase-1 | |
IL246902A0 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
IL250876B (en) | Inhibitors of lysine specific demethylase-1 | |
IL249733B (en) | Inhibitors of lysine specific demethylase-1 | |
IL249876B (en) | Inhibitors of lysine specific demethylase-1 | |
IL248567A0 (en) | Use of known compounds as d-amino acid oxidase inhibitors |